| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 33.65 | -0.63 (-1.84%) | 25.01 - 38.32 | 386.1 thousand (Below Avg) |
Market data as of 1:06PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 34.09 |
|---|---|
| Previous Close | 34.28 |
| Day's Range | 33.51 - 34.11 |
| Market Cap | 3.8B |
| Avg Volume (10 Day) | 3.1M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -5.52 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone
PR Newswire - Friday 05/10/2013 4:56 PM ET
Endo Reports First Quarter Financial Results
PR Newswire - Tuesday 05/07/2013 7:00 AM ET
First Head-to-Head Study Shows GreenLight XPS® Laser Therapy Equally Safe And Effective With Faster Recovery As Commonly Used TURP For Treatment Of BPH
PR Newswire - Monday 05/06/2013 4:02 PM ET
| ENDP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 6.45% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 2.76 | |
| LT Debt/Equity | 2.70 | |
| Earnings Yield | -- | |
| Price/Sales | 1.26 |
| Company | Last | Change |
|---|---|---|
| Cubist Pharmaceuticals Inc | 55.45 | -1.04% |
| United Therapeutics Corp | 65.72 | -2.80% |
| Taro Pharmaceutical Industries Ltd | 59.70 | -5.57% |
| Warner Chilcott Plc | 19.81 | -0.98% |
| Isis Pharmaceuticals Inc | 20.82 | +0.87% |
Data is delayed by at least 15 min.